Abstract:Michaela S Seng, 1, 2 Amandine C Meierhofer, 3 Francesca L Lim, 2, 4 Shui Yen Soh, 1, 2 William YK Hwang 2, 4, 5 1 Department of Paediatric Hematology and Oncology, KK Women's and Children's Hospital, Singapore; 2 Duke-NUS Medical School, Singapore; 3 Heriot-Watt University, Edinburgh, Scotland; 4 Department of Hematology, Singapore General Hospital, Singapore; 5 National Cancer Centre Singapore, Singapore Correspondence: William YK Hwang, Department of Haematology, Singapore General Hospital, 31 Third Hospital Ave, 168753, Singapore, Tel +65 62223322, Email Approximately 10– 15% of pediatric B-cell acute lymphoblastic leukemia (B-ALL) are high risk at diagnosis or relapsed/ refractory. Prior to the availability of chimeric antigen receptor T-cell (CAR-T) in Singapore and the region, the treatment options for these paediatric and young adults are conventional salvage chemotherapy or chemo-immunotherapy regimens as a bridge to allogeneic total body irradiation-based hematopoietic stem cell transplantation (allo-HSCT). This results in significant acute and long-term toxicities, with suboptimal survival outcomes. Finding a curative salvage therapy with fewer long-term toxicities would translate to improved quality-adjusted life years in these children and young adults. In this review, we focus on the burden of relapsed/refractory pediatric B-ALL, the limitations of current strategies, the emerging paradigms for the role of CAR-T in r/r B-ALL, our local perspectives on the health economics and future direction of CAR-T therapies in pediatric patients. Keywords: cell therapy, relapsed, refractory, lymphoblastic leukemia, pediatric and young adult A range of mechanisms are used by the immune system to suppress cancer cells and many of these mechanisms are inactivated during the development of the cancer, allowing cancer cells to spread. Cancer immunotherapy is based on the notion that the immune response can be harnessed or reprogrammed to effectively eradicate cancer cells. As T cells play a crucial role in the adaptive immunity involved in tumor surveillance and pathogen clearance, they have been studied for their role in anti-cancer therapy. 1,2 In the 1970s, stem cell transplantation provided the first biological evidence that adoptive T cells from an MHC-compatible healthy donor could exert a powerful graft-versus-leukemia effect, leading to long-term eradication of chemo-refractory leukemias. The use of tumor-infiltrating lymphocytes by Rosenberg in 1986 to cure a subset of patients with advanced cancers 3 further supported the potential of adoptive T cell therapies. These early salvage therapies provided the foundation for the subsequent major advancements in T cell-based therapies. Sequential seminal innovations over the last 30 years contributed to the modular development of a clinically effective CAR-T construct. The first synthesis of a chimeric immunoglobulin/T-cell receptor (TCR) molecule, now known as the chimeric antigen receptor (CAR), led to the scientific plausibility that T-cells could be engineered with antibody type-specificity for therapy against specific targets. 4 Subsequently the first generation of effector T-cells expressing a CAR was conceived around 1989–1993 by Israeli immunologists Zelig Eshhar and Gideon Gross. 5,6 Around this time, Irving and Weiss showed that following extracellular antigen-binding, signal transduction through a transmembrane CD8 and intracellular TCR CD3ζ domain present in a CAR could independently mediate T-cell activation. 7 A significant boost to this field occurred when Michel Sadelain developed retroviral vectors as a method to introduce genes into T-cells, enabling large-scale modification of their cytotoxicity and specificity for cancer cells. 8 The first-generation synthetic CAR that is expressed from the T cells reprograms lymphocyte function and specificity by the coupling of the intracellular T-cell signaling domains and the antigen-binding single chain Fv domain (scFv), bypassing the need for native major histocompatibility complex (MHC)-restricted T-cell activation. This worked modestly but lacked the proliferation, persistence and potency needed for effective cancer killing. This was primarily due to the lack of a second signal for T-cell activation, the co-stimulatory signal. These limitations were overcome in the second-generation construct which linked the antigen-binding activation of intracellular T-cell signaling (Signal 1) to a single co-stimulatory signal (Signal 2), either a 41BBz or CD28 module; this ingenious modification formed the basis of the first clinically effective CAR-T therapies. 9,10 More than a decade -Abstract Truncated-

Utilizing distinct CAR and TCR signaling to generate enhanced cellular immunotherapy

A Chimera Antigen Receptor Containing TLR4 Signaling Domain Enhances CAR-iMACs Polarization and Potency against Solid Tumors

Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy

Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs)

Abstract PR-02: CRISPR/Cas9 Engineering of Next-Generation Armoured CAR T Cells

Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma

Dissecting the role of CAR signaling architectures on T cell activation and persistence using pooled screening and single-cell sequencing

Abstract 3609: Chimeric cytokine receptors increase memory phenotypes and improve expansion and efficacy of CAR-T cell therapies

Abstract 58: Immunocytokines with specificity for invariant region of CAR molecules enhance effector function of multiple CAR T cell therapies

A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects

A Review of CAR-T Therapy in Pediatric and Young Adult B-Lineage Acute Leukemia: Clinical Perspectives in Singapore

Abstract 3995: A novel chimeric Fas signal redirect receptor enhances the durability of anti-tumor activity and serial killing potential of CAR T cells

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer

Abstract 39: Preclinical in vitro and in vivo evaluation of CD8αβ+ CD19 CAR iPSCs T cells generated in a TCR signal-independent manner using DLL4/VCAM-coupled microbeads

Click CAR-T cell engineering for robustly boosting cell immunotherapy in blood and subcutaneous xenograft tumor

Abstract 5568: Revitalization of affinity-tuned CAR T cells via antigen-dependent release of interleukin-12

Abstract 1780: TCR-T and CAR-T cells targeting HLA-A2/MAGEA4 demonstrate differential tumor control, reflecting co-stimulatory signaling requirements

From TCR fundamental research to innovative chimeric antigen receptor design

Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells

Abstract 882: Harnessing single cell multi-omics data to identify predictors of clinical outcome in CD19 CAR T cell therapy